Poster presentations 3% (1-5) in IBD (4% of total CD4+ T cells) and 5% (5-7) in HC (11% of total CD4+ T cells, p = 0.007). The %CD3+CD103+CD8+ in IBD was 9% (4-15, 33% of total CD8+ T cells) and in HC 42% (23-57, 83% of total CD8+ T cells, p = 0.001). The majority of CD3+CD103-T-cell subsets in active IBD at baseline was represented by CD103-CD4+ T cells (65% (52-74), in HC 30% (21-50), p = 0.001), while and in HC 13% (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), p = 0.001). When endoscopic remission is seen in IBD patients during follow-up, all frequencies of CD103+ T-cell subsets approach percentages comparable to HC. Conclusions: Active mucosal inflammation in IBD patients is associated with decreased percentages CD3+CD103+ T-cell subsets. The CD103+ CD8+ T-cell subset is lower in active disease compared with healthy controls. Endoscopic remission in IBD is associated with normalisation of the mucosal T-cell profiles, also the CD103+CD8+ T-cell subset. The suggested pro-inflammatory CD103+ CD4+ T cells represented only a minority of the total mucosal (CD103+) T-cell subset. It is mainly the CD4+CD103− T-cell subset that infiltrates the inflamed colon in IBD. These results challenge the pro-inflammatory role of these CD103+CD4+ T cells in IBD patients. Background: Crohn disease in some paediatric and adolescent patients is presented with cachexic status manifested with malabsorption, nutritional deficiencies, osteopenia, sarcopenia, and growth failure. Though different with cancer cachexia, underlying pathogenic mechanisms share similarity. Stimulated with cancer cachexia pathogenesis, we have challenged TNF-alpha antibodies, adalimumab and biosimilar of infliximab, Remsima, in animal model with cancer cachexia because significant surge up in TNF-α and IL-6 was prevailing condition in cachexia. Methods: Humira and its biosimilar Remsia were administered three times per week in mice xenografted with C26 adenocarcinoma cells up to 3 weeks of cachexia condition. Results: As results, adalimumab and Remsima significantly ameliorated cancer cachexia, presenting with significantly lowered mice survival, attenuated weight loss, appetite preservation as well as preserved skeletal muscle and abdominal fats (p < 0.01). Genes including PAX7, muscle related genes such as MurF-1, antrogin-1, and Mul-1 were significantly attenuated along with significant decreased TNF-α serum levels (p < 0.01). Experiments were repeated in Min mice model, which showed cachexic status as intestinal polyposis progressed, administered with DSS to simulate CD manifestation. As results, cachexic status was significantly ameliorated in group treated with either adalimumab or infliximab biosimilar.
Background: Crohn disease in some paediatric and adolescent patients is presented with cachexic status manifested with malabsorption, nutritional deficiencies, osteopenia, sarcopenia, and growth failure. Though different with cancer cachexia, underlying pathogenic mechanisms share similarity. Stimulated with cancer cachexia pathogenesis, we have challenged TNF-alpha antibodies, adalimumab and biosimilar of infliximab, Remsima, in animal model with cancer cachexia because significant surge up in TNF-α and IL-6 was prevailing condition in cachexia. Methods: Humira and its biosimilar Remsia were administered three times per week in mice xenografted with C26 adenocarcinoma cells up to 3 weeks of cachexia condition. Results: As results, adalimumab and Remsima significantly ameliorated cancer cachexia, presenting with significantly lowered mice survival, attenuated weight loss, appetite preservation as well as preserved skeletal muscle and abdominal fats (p < 0.01). Genes including PAX7, muscle related genes such as MurF-1, antrogin-1, and Mul-1 were significantly attenuated along with significant decreased TNF-α serum levels (p < 0.01). Experiments were repeated in Min mice model, which showed cachexic status as intestinal polyposis progressed, administered with DSS to simulate CD manifestation. As results, cachexic status was significantly ameliorated in group treated with either adalimumab or infliximab biosimilar.
Conclusions:
In conclusion, top-down administration of biologics targeting TNF-α should be considered in paediatric or adolescent CD patients presenting with severe wasting conditions
P090 Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?
A.G. Background: Epstein-Barr virus (EBV) has been associated with inflammation in the colon, particularly in patients with inflammatory bowel diseases, even if its potential impact on pathophysiology and course of the disease is still unclear. Conversely, no data are available on the association between EBV and microscopic colitis (MC). We aimed to compare the frequency of colonic EBV infection in patients with MC, ulcerative colitis (UC), and irritable bowel syndrome (IBS). Methods: The frequency of colonic EBV infection in biopsies of 30 patients with MC, 30 patients with UC, and 30 controls with IBS was retrospectively assessed. PCR was performed to detect viral EBV DNA in colonic biopsies. In situ hybridisation was also performed to identify and localise EBV-encoded small RNAs (EBERs) within cells, which are known to play a role in inhibition of apoptosis, increase of cell proliferation, and induction of pro-inflammatory cytokines. Conclusions: This study shows for the first time that EBV infection is almost always detectable in patients with MC. The high frequency of EBERs+ cells observed in MC suggests that EBV may act deeper than as an innocent bystander, as it could play a causative role in the pathogenesis of the disease. Further studies are necessary to confirm this association and to clarify the role of EBV in MC and, more generally, in colonic inflammation.
P091
Inflammation in relation to mucosal barrier function in chronic colitis: a study in time
